Camille L Swartz,
Clinical Research Coordinator III
Department:
MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone:
(352) 733-2429
Business Email:
cami.swartz@neurology.ufl.edu
Publications
Academic Articles
2024
Immunophenotyping Tracks Motor Progression in Parkinson’s Disease Associated with a TH Mutation.
Journal of Parkinson's disease.
14(4):883-888
[DOI] 10.3233/JPD-240030.
[PMID] 38788089.
2014
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
JAMA neurology.
71(5):543-52
[DOI] 10.1001/jamaneurol.2014.131.
[PMID] 24664227.
2012
Selection of deep brain stimulation candidates in private neurology practices: referral may be simpler than a computerized triage system.
Neuromodulation : journal of the International Neuromodulation Society.
15(3):246-50; discussion 250
[DOI] 10.1111/j.1525-1403.2012.00437.x.
[PMID] 22376158.
2010
Prevalence and characteristics of punding and repetitive behaviors among Parkinson patients in North-Central Florida.
International journal of geriatric psychiatry.
25(5):540-1
[DOI] 10.1002/gps.2324.
[PMID] 20391589.
2003
Respiratory response to activation or disinhibition of the dorsal periaqueductal gray in rats.
Journal of applied physiology (Bethesda, Md. : 1985).
94(3):913-22
[PMID] 12571126.
Grants
Nov 2021
– Jun 2023
A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE
Role: Other
Funding: GENENTECH INC
Oct 2020
– Oct 2025
A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure
Role: Other
Funding: IQVIA Holdings
via DRUGDEV INC
May 2020
– Nov 2023
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinsons Disease
Role: Other
Funding: NEURALY
Jan 2020
– Jan 2025
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients with ALS: Open-Label Extension for Patients Completing Study 3119002
Role: Other
Funding: PHARMACEUTICAL RES ASSO
via ORION CORP
Aug 2018
– Aug 2023
Local Field Potential Beta Adaptive Deep Brain Stimulation Feasibility Study (LFP Beta aDBS Feasibility Study)
Role: Other
Funding: MEDTRONIC INC
Contact Details
Phones:
- Business:
- (352) 733-2429
Emails:
- Business:
- cami.swartz@neurology.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 112742
GAINESVILLE FL 32611 - Business Street:
-
3009 SW WILLISTON RD
GAINESVILLE FL 32608